Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1987-2-6
|
pubmed:abstractText |
Treatment with continuous infusions of cisplatin results in increased filterable drug exposures as measured by the area under the curve (AUC) of nonprotein-bound plasma platinum levels. To determine the dose-limiting toxicity and optimal method of administration, 24 patients were treated with continuous infusions of cisplatin at a dose rate of 25 mg/M2/day in a limited Phase I trial. A total of 47 courses were given. Nine patients received 13 courses of 4 days duration, 19 received 29 courses of 5 days duration, and five received courses of 6 or 7 days duration. Dose-limiting toxicity was found to be leukopenia: 42% of patients receiving the 5-day treatment developed a nadir count of less than 3000 cells/mm3. Nausea and vomiting were easily controlled. Minimal nephrotoxicity occurred in five patients and was associated with daily volume expansion with 2 l of 0.9% NaCl solution in four patients. All other patients were given 3 l of daily volume expansion during treatment. Responses were seen in 6 of 22 evaluable patients (27%). It is concluded that continuous infusion cisplatin at a dose rate of 25 mg/M2/day can be given safely for 5 days as a single agent if concomitant volume expansion with at least 3 l of 0.9% NaCl solution is given daily. Phase III comparative trials with a conventional bolus and newer high-dose regimens for response and toxicity are indicated.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0008-543X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
59
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
15-8
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:3791142-Adult,
pubmed-meshheading:3791142-Aged,
pubmed-meshheading:3791142-Cisplatin,
pubmed-meshheading:3791142-Drug Evaluation,
pubmed-meshheading:3791142-Female,
pubmed-meshheading:3791142-Hematologic Diseases,
pubmed-meshheading:3791142-Humans,
pubmed-meshheading:3791142-Infusions, Intravenous,
pubmed-meshheading:3791142-Kidney Diseases,
pubmed-meshheading:3791142-Male,
pubmed-meshheading:3791142-Middle Aged,
pubmed-meshheading:3791142-Neoplasms
|
pubmed:year |
1987
|
pubmed:articleTitle |
A phase I trial of continuous infusion cisplatin.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|